Urgent.News

600+ sources. One page. See who else covered it.

Editions

Health & Medicine

Radiopharmaceutical may benefit patients with metastatic prostate cancer sooner

Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a trio of drugs, according to a Phase III clinical trial led by Weill Cornell Medicine, NewYork-Presbyterian, Memorial Sloan Kettering Cancer Center and investigators at several other institutions worldwide.

Radiopharmaceutical may benefit patients with metastatic prostate cancer sooner

We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.

Read the original at medicalxpress.com →

More in Health & Medicine

More from Friday 7 August →